Siemens Healthineers Pushes Neuro Innovation and €230m Buyback as Spin-Off and Diagnostics Drag Loom

Siemens Healthineers launches €230M buyback, partners with Mentice for stroke care, appoints former Google Brain CTO, as stock near 52-week low.

The stock is hovering just over €34, barely four percent above its 52-week trough, after shedding about a fifth of its value since January. Siemens Healthineers is responding with a trio of strategic moves: a €230 million share buyback, a technology partnership targeting stroke care, and a sweeping leadership overhaul — all while its parent company prepares to sever direct control.

Buyback at Bargain Levels

The company has launched a programme to repurchase up to 14 million shares, worth a maximum of €230 million, with the proceeds earmarked for employee compensation and staff share schemes. The buyback runs until 29 January 2027 and is taking place at what are effectively floor prices. The shares are changing hands at €34.71, not far above the year's low of €33.34. Since the start of the calendar year they have lost around 22 percent.

Neuro Technology Tie-Up

Alongside the buyback, Siemens Healthineers has struck a cooperation agreement with Mentice, a specialist in medical simulation. The principle: Mentice's Ankyras software will be integrated into the ARTIS icono angiography systems. Clinicians will be able to send imaging data directly to the platform, allowing them to plan and simulate treatments for cerebral aneurysms virtually. The software forecasts how flow-diverting stents will behave — predicting shortening and landing zones. Joint marketing activities are also part of the deal, all aimed at making neuro-intervention workflows more efficient.

Four New Leaders, One New CTO

The management reshuffle is the most extensive in recent memory. Four senior appointments took effect on 1 June, with a fifth arriving in October.

Andreas Schneck now runs Diagnostic Imaging, succeeding André Hartung, who leaves after 25 years. Schneck previously led the global MRI business for three years and, before that, built the MRI operation in Shenzhen from 2020 to 2023.

Philipp Fischer takes over Advanced Therapies. A trained physician who has been at the company since 2009, he has run cardiovascular and CT segments since 2019. He replaces Carsten Bertram, who will stay on until 2027 to support the new chief technology officer.

Sonja Wehsely, a 2017 recruit, now heads the Europe, Middle East and Africa region, which covers about 30 countries. She takes the reins from Bernd Ohnesorge, who stepped down after eight years for personal reasons.

Martin Stumpe is the most eye-catching hire. The former Google Brain developer joins as chief technology officer in June and will drive the AI strategy in healthcare. The outgoing CTO, Peter Schardt, is leaving the company along with three other executives.

Elaine Becraft will become chief human resources officer on 1 October. She currently leads HR inside the Diagnostics segment.

Diagnostics in the Doldrums

The new executives walk into a mixed business environment. In the second quarter of fiscal 2026, Diagnostics revenues slid 6.5 percent, hit by conditions in China. By contrast, Imaging grew 6.1 percent and Precision Therapy added 4.7 percent. The diagnostics unit has also attracted preliminary takeover interest: private-equity firms are said to be circling with bids of €6 billion or more, though talks are not final and Siemens Healthineers may yet choose to retain the division.

Spin-Off Countdown to February 2027

The leadership changes coincide with a fundamental corporate restructuring. Siemens AG will put a direct spin-off of its majority stake to a shareholder vote at the next annual general meeting in February 2027. Under the plan, Siemens shareholders would receive Healthineers shares directly, with the transaction structured under the German Transformation Act. The parent currently owns just over 67 percent of Healthineers and aims to cut that to below 20 percent over time. At present, Siemens guarantees loans of up to €13.9 billion for the subsidiary; after the separation that backstop disappears. A syndicate of banks is said to be ready to provide future refinancing.

What Investors Will Hear Next

On 3 June, management will hold a roadshow in Luxembourg with Berenberg, addressing institutional investors on the new leadership team and the strategic direction. Third-quarter results are due in July. With the stock near its lows, a buyback under way, a spin-off on the horizon, and a new CTO who built AI at Google, the next few months will test whether the company can convince the market that the turnaround narrative is more than just a series of announcements.